MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 574772 | Name: Lumifusidic Acid

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Lumifusidic Acid is a derivative of Fusidic Acid -- a bacteriostatic antibiotic. Fusidic Acid suppresses nitric oxide lysis of pancreatic islet cells and inhibits protein synthesis in prokaryotes by inhibiting the ribosome-dependent activity of G factor and translocation of peptidyl-tRNA.

Chemical Structure

Lumifusidic Acid
Lumifusidic Acid
CAS#3482-49-3

Theoretical Analysis

MedKoo Cat#: 574772

Name: Lumifusidic Acid

CAS#: 3482-49-3

Chemical Formula: C31H48O6

Exact Mass: 516.3451

Molecular Weight: 516.72

Elemental Analysis: C, 72.06; H, 9.36; O, 18.58

Price and Availability

Size Price Availability Quantity
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
Lumifusidic Acid
IUPAC/Chemical Name
(E)-2-((3R,4S,5S,8S,9S,10S,11R,13R,14S,16S)-16-acetoxy-3,11-dihydroxy-4,8,10,14-tetramethylhexadecahydro-17H-cyclopenta[a]phenanthren-17-ylidene)-6-methylhept-5-enoic acid
InChi Key
IECPWNUMDGFDKC-UEVMROTKSA-N
InChi Code
InChI=1S/C31H48O6/c1-17(2)9-8-10-20(28(35)36)26-22-15-24(34)27-29(5)13-12-23(33)18(3)21(29)11-14-30(27,6)31(22,7)16-25(26)37-19(4)32/h9,18,21-25,27,33-34H,8,10-16H2,1-7H3,(H,35,36)/b26-20+/t18-,21-,22-,23+,24+,25-,27-,29-,30-,31-/m0/s1
SMILES Code
O[C@@H]1CC[C@@]2(C)[C@](CC[C@@]([C@](C[C@H](OC(C)=O)/C3=C(CC/C=C(C)\C)/C(O)=O)(C)[C@@]3([H])C[C@H]4O)(C)[C@]24[H])([H])[C@@H]1C
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Product Data
Instruction
View handling instruction
Biological target:
Lumifusidic Acid is a derivative of Fusidic Acid -- a bacteriostatic antibiotic.
In vitro activity:
Fusidic acid treatment decreased the number of T. gondii plaques in a dose-dependent manner, with a half maximal inhibitory concentration (IC50) of ~4 μg/ml (Fig. 1). Fusidic acid inhibited a T. gondii mutant with a dramatic reduction in TgEFG levels, highlighting that either TgEFG levels are in excess of that required for tissue culture growth or that TgEFG is not the only target of fusidic acid. Overall, these results show that fusidic acid is effective against T. gondii in tissue culture, and suggest that it might be a useful treatment against T. gondii during animal infection. Reference: Parasitol Res. 2013 Nov; 112(11): 3859–3863. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4096717/
In vivo activity:
Untreated EAM animals exhibited discolored areas over the cardiac surface (mean macroscopic score 1.8) and severe inflammatory lesions were observed microscopically in the myocardium (Fig. 1a). These lesions were composed of marked infiltration by inflammatory cells including lymphocytes, macrophages and neutrophils. In contrast, in the EAM rats treated with fusidine from days 0 to 10 (group A) there was little inflammatory cells infiltration in the myocardium and cardiac myocytes were well preserved (Fig. 1b). In late treatment group B, only focal infiltration by inflammatory cells was detected and necrosis limited to cardiac myocytes that were in contact with the inflammatory cells (Fig. 1f). The mean microscopic score was still markedly lower than that of untreated animals (Table 1). Reference: Pharmacol Res. 2005 Dec;52(6):491-6. https://pubmed.ncbi.nlm.nih.gov/16216521/

Preparing Stock Solutions

The following data is based on the product molecular weight 516.72 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Park E, Kim DK, Kim CS, Kim JS, Kim S, Chun HS. Protective effects of fusidic acid against sodium nitroprusside-induced apoptosis in C6 glial cells. Neuroreport. 2019 Dec 10;30(17):1222-1229. doi: 10.1097/WNR.0000000000001354. PMID: 31651708. 2. Payne AJ, Neal LM, Knoll LJ. Fusidic acid is an effective treatment against Toxoplasma gondii and Listeria monocytogenes in vitro, but not in mice. Parasitol Res. 2013 Nov;112(11):3859-63. doi: 10.1007/s00436-013-3574-1. Epub 2013 Aug 16. PMID: 23949312; PMCID: PMC4096717. 3. Milenkovć M, Arsenović-Ranin N, Vucićević D, Bufan B, Stojić-Vukanić Z. Fusidin ameliorates experimental autoimmune myocarditis in rats by inhibiting TNF-alpha production. Pharmazie. 2007 Jun;62(6):445-8. PMID: 17663192. 4. Milenković M, Vucićević D, Milosavljević P, Ranin NA, Vukanić ZS, Colić M. Suppression of experimental autoimmune myocarditis by sodium fusidate (fusidin). Pharmacol Res. 2005 Dec;52(6):491-6. doi: 10.1016/j.phrs.2005.08.001. Epub 2005 Oct 7. PMID: 16216521.
In vitro protocol:
1. Park E, Kim DK, Kim CS, Kim JS, Kim S, Chun HS. Protective effects of fusidic acid against sodium nitroprusside-induced apoptosis in C6 glial cells. Neuroreport. 2019 Dec 10;30(17):1222-1229. doi: 10.1097/WNR.0000000000001354. PMID: 31651708. 2. Payne AJ, Neal LM, Knoll LJ. Fusidic acid is an effective treatment against Toxoplasma gondii and Listeria monocytogenes in vitro, but not in mice. Parasitol Res. 2013 Nov;112(11):3859-63. doi: 10.1007/s00436-013-3574-1. Epub 2013 Aug 16. PMID: 23949312; PMCID: PMC4096717.
In vivo protocol:
1. Milenkovć M, Arsenović-Ranin N, Vucićević D, Bufan B, Stojić-Vukanić Z. Fusidin ameliorates experimental autoimmune myocarditis in rats by inhibiting TNF-alpha production. Pharmazie. 2007 Jun;62(6):445-8. PMID: 17663192. 2. Milenković M, Vucićević D, Milosavljević P, Ranin NA, Vukanić ZS, Colić M. Suppression of experimental autoimmune myocarditis by sodium fusidate (fusidin). Pharmacol Res. 2005 Dec;52(6):491-6. doi: 10.1016/j.phrs.2005.08.001. Epub 2005 Oct 7. PMID: 16216521.